Evidence map›Paper›PMID 35079699›Full record

ArticleJHEP reports : innovation in hepatology2022

Incidence of hepatocellular carcinoma in a community-based Taiwanese population without chronic HBV/HCV infection.

Hui-Chen Wu, Wen-Juei Jeng, Mei-Hung Pan, Yi-Chung Hsieh, Sheng-Nan Lu, Chien-Jen Chen, Hwai-I Yang

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in JHEP reports : innovation in hepatology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed, 1 pooled it
1.2field-weighted citation impact, top 20% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 1 synthesis or guideline pooled it, 13 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 6 institutions in 2 countries.

Hui-Chen WuDepartment of Environmental Health Sciences, Mailman School of Public Health of Columbia University, New York, NY, USA.
Wen-Juei JengDivision of Hepatogastroenterology, Chang Gung Memorial Hospital, Taoyuan City, Taiwan.
Mei-Hung PanGenomics Research Center, Academia Sinica, Taipei, Taiwan.
Yi-Chung HsiehDivision of Hepatogastroenterology, Chang Gung Memorial Hospital, Taoyuan City, Taiwan.
Sheng-Nan LuDivision of Hepato-Gastroenterology, Department of Internal Medicine, ChiayiChang Gung Memorial Hospital, Chiayi, Taiwan.
Chien-Jen ChenGenomics Research Center, Academia Sinica, Taipei, Taiwan.
Hwai-I YangGenomics Research Center, Academia Sinica, Taipei, Taiwan.
Chang Gung University · TWChiayi Chang Gung Memorial Hospital · TWColumbia University Irving Medical Center · USGenomics Research Center, Academia Sinica · TWNational Taiwan University · TWNational Yang Ming Chiao Tung University · TW

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

BACKGROUND &

aimsIn addition to HBV/HCV causing hepatocellular carcinoma (HCC), other risk factors including obesity and alcohol drinking also increase risk. We describe the cumulative risk of HCC and mortality from liver-related disease by selected modifiable risk factors among a non-hepatitis virus-infected population.

methodsFor a community-based cohort, residents aged 30-65 years living in 7 townships in Taiwan were recruited, and have been followed up since 1991. A total of 18,541 individuals were seronegative for markers of chronic infection of HBV/HCV and with no history of HCC at baseline. New non-HBV/HCV HCC cases and liver-related deaths were ascertained through data linkage to the National Cancer Registry and Death Certification System from 1 January 1991 through 31 December 2017.

resultsThere were 207 HCC cases and 215 liver-related deaths identified. The incidence rate of non-HBV/HCV HCC was 47.2 per 100,000 person-years. The mortality rate of liver-related death was 49.0 per 100,000 person-years. Baseline information on alcohol consumption, heart disease, diabetes, elevated aspartate aminotransferase, and alanine aminotransferase predicted higher risks of HCC, with hazard ratios (HRs) (95% CIs) of 1.7 (1.1-2.5), 2.2 (1.1-4.1), 1.9 (1.0-3.5), 1.7 (1.1-2.4), and 1.6 (1.0-2.4), respectively. The HRs (95% CIs) of liver-related death were 2.3 (1.6-3.2) for alcohol consumption, 1.4 (1.1-1.9) for BMI ≥25 kg/m

conclusionsIndividuals with elevated liver enzymes are at high risk of liver disease. Prevention and treatment of diabetes and heart disease are critical for non-hepatitis B, non-hepatitis C (NonB/C)-HCC. LAY SUMMARY: We followed up individuals with no chronic HBV or HCV infection and described the risk of hepatocellular carcinoma (HCC, the most common form of primary liver cancer) and mortality from liver-related disease by modifiable risk factors. This study estimated the incidence rate of HCC by selected lifestyle risk factors and chronic diseases conditions. Alcohol consumption, heart disease, diabetes, and abnormal blood liver function tests showed a strong association with HCC risk and mortality.

Indexed as

AFP, α-foetoproteinAlcohol drinkingALT, alanine aminotransferaseanti-HCV, antibodies against HCVAST, aspartate aminotransferaseCLD, chronic liver diseaseCSP, Cancer Screening ProgramCumulative incidenceDiabetesEpidemiologyFIB-4, fibrosis-4HBc, hepatitis B coreHBcrAg, hepatitis B core-related antigenHBsAg, hepatitis B surface antigenHCC, hepatocellular carcinomaHepatocellular carcinomaHR, hazard ratioICD-10, International Classification of Diseases 10th RevisionICD-9, International Classification of Disease 9th RevisionLiver-related deathLRD, liver-related deathNonB/C-HCC, non-hepatitits B, non-hepatitis C-hepatocellular carcinomaNonB/C-LRD, non-hepatitis B, non-hepatitis C virus liver-related deathNon-hepatitis Bnon-hepatitis C HCCNon-viral HCCObesityPAR%, population attribute risk percentageSmokingWHO, World Health Organization

Identifiers

PMID35079699
PMCPMC8777288
OpenAlexW3215268224

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.